Maintenance therapy with biweekly cetuximab (C) in the first-line treatment of metastatic colorectal cancer (mCRC): The NORDIC 7.5 study (NCT00660582), by the Nordic Colorectal Cancer Biomodulation Group.

Per Pfeiffer,Halfdan Sorbye,Camilla Qvortrup,Mia Karlberg,Gisela Naucler,Christian Kersten,Kirsten Vistisen,Birgitta Lindh,Bengt Glimelius

Maintenance therapy with biweekly cetuximab (C) in the first-line treatment of metastatic colorectal cancer (mCRC): The NORDIC 7.5 study (NCT00660582), by the Nordic Colorectal Cancer Biomodulation Group.

2017

Per Pfeiffer
Halfdan Sorbye
Camilla Qvortrup
Mia Karlberg
Gisela Naucler
Christian Kersten
Kirsten Vistisen
Birgitta Lindh
Bengt Glimelius

3538 Background: NORDIC 7.5 is a multi-center phase II trial of Nordic FLOX plus biweekly C followed by maintenance C in first-line treatment of mCRC, KRASwild-type (KRASwt). The aim was to complem...

Keywords:

Oncology
Colorectal cancer
Medicine
Maintenance therapy
Physical therapy
Internal medicine
Cetuximab
first line treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations